March 4, 2013
Atlanta, Ga. -- The U.S. Women and PrEP Working Group, a coalition of more than 50 women from leading AIDS and women's health organizations, today called on US government agencies to coordinate a national agenda that will quickly and accurately answer questions about how the antiretroviral (ARV) drug Truvada can best be made available as an HIV prevention option for women at risk of HIV infection.
The Working Group called for a US federal coordinating group to be convened with the goal of ensuring that plans and funds are in place for demonstration projects that will answer key questions about the use of daily tenofovir/emtricitibine (TDF/FTC, brand name Truvada) as pre-exposure prophylaxis (PrEP) among women in the United States, as well as plans for educational campaigns for women, their partners and health care providers as PrEP is rolled out. Read the full press release here ...
AVAC, Sisterlove, and partners will host a community event this evening, March 4, to discuss these results and the next steps in ARV-based prevention. The event will take place from 6:30-8:30pm at the Loudermilk Center in Atlanta, GA, 40 Courtland Street, NE. RSVP at this email.
For those not in Atlanta, please join advocates for a post-CROI webinar featuring VOICE trial investigators and those in the field to discuss recent results next Monday, March 11, 2013 at 6am US PAcific/9am US Eastern. Register for the webinar here.
Read PWN-USA's blog, U.S. Positive Women's Network